comparemela.com

Latest Breaking News On - Antonio breast cancer - Page 32 : comparemela.com

New Data Presented at SABCS 2021 Strengthen Value of Oncotype DX Breast Recurrence Score® Test to Inform Clinical Decision-making

New Data Presented at SABCS 2021 Strengthen Value of Oncotype DX Breast Recurrence Score® Test to Inform Clinical Decision-making Updated RxPONDER study analysis provides further evidence that the test identifies the majority of women with early-stage, node-positive breast cancer who can avoid chemotherapy.

San antonioUnited statesKevin kalinskyRick baehnerSciences corpNational cancer instituteCancer research networkPrecision oncology at exact sciencesSciences on twitter exactsciencesNew data presentedInform clinicalExact sciencesAntonio breast cancerRecurrence scoreResearch networkPrecision oncology

Watch and Switch Strategy Extends PFS in HR-Positive Breast Cancer

Progression-free survival doubled with treatment change based on monitoring for resistance marker

France generalUnited statesFort pierceMayo clinic in rochesterSan antonioEd susmanInstitut curie universitCirculating tumorSan antonio breast cancerMayo clinicAntonio breast cancer

Breast Cancer-Related Lymphedema More Common Among Black Women

Black women experienced higher rates of breast cancer-related lymphedema compared with White women, with Black race being the strongest predictor.

San antonioUnited statesAndreav barrioChanel endowment for survivorship researchManhasset women coalition against breast cancerDepartment of surgeryBreast serviceMemorial sloan kettering cancer centerAntonio breast cancerCancer therapy advisorAntonio breast cancer symposiumMemorial sloan kettering cancerChanel endowmentSurvivorship researchManhasset womenCoalition against breast

CDK7 Inhibitor-Based Combo Promising in CDK4/6-Resistant Breast Cancer

Clinical benefit rate of 36%, plus tumor shrinkage, with samuraciclib plus fulvestrant

San antonioUnited statesCity ofUnited kingdomAngela demicheleMike bassettCharles coombesImperial college londonUniversity of pennsylvaniaPerelman school of medicineImperial collegeSan antonio breast cancerPerelman schoolAntonio breast cancer

Recurrence Risk Reduced With AI vs Tamoxifen in Premenopausal ER+ Breast Cancer

An aromatase inhibitor reduced risk of recurrence in women undergoing ovarian suppression for ER+ breast cancer, compared with tamoxifen.

San antonioUnited statesUnited kingdomRosie bradleyUniversity of oxfordAntonio breast cancerAntonio breast cancer symposium

vimarsana © 2020. All Rights Reserved.